Prudential Financial
DSGN icon

Prudential Financial’s Design Therapeutics DSGN Stock Holding History

Prudential Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.24M Buy
224,170
+178,360
+389% +$2.22M ﹤0.01% 1193
2026
Q1 		$487K Buy
45,810
+3,100
+7% +$31.4K ﹤0.01% 1877
2025
Q4 		$401K Sell
42,710
-2,115
-5% -$16.6K ﹤0.01% 1902
2025
Q3 		$338K Sell
44,825
-13,100
-23% -$65.6K ﹤0.01% 2070
2025
Q2 		$195K Buy
57,925
+1,520
+3% +$5.69K ﹤0.01% 2217
2025
Q1 		$218K Buy
56,405
+90
+0.2% +$429 ﹤0.01% 2058
2024
Q4 		$347K Sell
56,315
-2,800
-5% -$16.2K ﹤0.01% 1951
2024
Q3 		$318K Sell
59,115
-4,100
-6% -$19.3K ﹤0.01% 2380
2024
Q2 		$212K Buy
63,215
+16,400
+35% +$63.9K ﹤0.01% 2468
2024
Q1 		$189K Buy
46,815
+28,400
+154% +$75.9K ﹤0.01% 2477
2023
Q4 		$48.8K Hold
18,415
– – ﹤0.01% 2552
2023
Q3 		$43.5K Sell
18,415
-7,800
-30% -$36.4K ﹤0.01% 2514
2023
Q2 		$165K Buy
+26,215
New +$160K ﹤0.01% 2452

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prudential Financial's DSGN Position: Q2 2026 in Review

Prudential Financial increased its Design Therapeutics (DSGN) stake by 389% in Q2 2026, buying an estimated $2.22M and bringing the position to 224,170 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1193.

Prudential Financial first reported a position in DSGN in Q2 2023 and has held it in 13 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Prudential Financial held 224,170 shares of Design Therapeutics worth $3.24M as of Q2 2026.
  • Prudential Financial bought 178,360 Design Therapeutics shares in Q2 2026, an estimated $2.22M.
  • Design Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1193 holding.
  • Prudential Financial first reported a position in Design Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.